Key Takeaway: Acadia Pharmaceuticals has received marketing authorization from the European Commission for DAYBU (trofinetide), the first treatment approved for neurobehavioral symptoms of Rett syndrome in the EU. This approval is a significant advancement for patients aged five years and older, providing a new therapeutic option for managing this condition.
Market Sentiment Analysis
POSITIVE FACTORS
DAYBU is the first approved treatment for Rett syndrome in the EU.
The approval represents a significant milestone for patients and families.
It is expected to improve the quality of life for those affected by Rett syndrome.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
5.6%
average across 7 past catalysts
Lead asset
Pimavanserin
Phase 2 · Agitation and Aggression in Alzheimer's Disease
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad
Frequently Asked Questions
What is DAYBU approved for?
DAYBU is approved for treating neurobehavioral symptoms of Rett syndrome.
Who can use DAYBU?
DAYBU is approved for adults and pediatric patients aged five years and older.
What does the approval of DAYBU signify?
It marks a significant milestone for the Rett syndrome community in the EU.
Is DAYBU the only treatment for Rett syndrome?
Yes, it is the first and only treatment approved for Rett syndrome in the EU.